We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-9.99%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$173M
AUM Growth
-$38.5M
(-18%)
Cap. Flow
-$5.29M
Cap. Flow
% of AUM
-3.06%
Top 10 Holdings %
Top 10 Hldgs %
57.59%
Holding
58
New
12
Increased
14
Reduced
11
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$7.43M |
| 2 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$6.54M |
| 3 |
Labcorp
LH
|
+$6.2M |
| 4 |
United Therapeutics
UTHR
|
+$6.1M |
| 5 |
Tenet Healthcare
THC
|
+$5.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$8.32M |
| 2 |
Merck
MRK
|
+$7.09M |
| 3 |
CVS Health
CVS
|
+$5.06M |
| 4 |
Exelixis
EXEL
|
+$4.53M |
| 5 |
Gilead Sciences
GILD
|
+$4.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.07% |
| 2 | Consumer Staples | 2.98% |
| 3 | Technology | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLGC
26
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $1.58M | 0.92% |
350,000
+55,000
| +19% | +$327K |
|
27
Ascendis Pharma A/S
ASND
$16B
| $1.39M | 0.81% |
+15,000
| New | +$1.41M |
|
28
Tactile Systems Technology
TCMD
$635M
| $1.28M | 0.74% |
175,000
+52,244
| +43% | +$662K |
|
29
DocGo
DCGO
$64.3M
| $1.25M | 0.72% |
175,000
+65,000
| +59% | +$474K |
|
30
InMode
INMD
$870M
| $1.12M | 0.65% |
50,000
-80,000
| -62% | -$2.1M |
|
|
VRAY
31
DELISTED
ViewRay, Inc.
VRAY
| $1.06M | 0.61% |
400,000
-200,000
| -33% | -$602K |
|
|
NXGN
32
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $1.05M | 0.61% |
60,000
+10,000
| +20% | +$191K |
|
33
RadNet
RDNT
$5.02B
| $864K | 0.5% |
50,000
| – | – |
|
|
DMTK
34
DELISTED
DermTech, Inc. Common Stock
DMTK
| $554K | 0.32% |
100,000
+50,000
| +100% | +$409K |
|
35
CareDx
CDNA
$2.26B
| $537K | 0.31% |
+25,000
| New | +$693K |
|
36
Plexus
PLXS
$6.72B
| $471K | 0.27% |
6,000
+1,000
| +20% | +$81.1K |
|
37
CALL
iShares S&P 100 ETF
OEF
$20.1B
| $318K | 0.18% |
+2,500
| New | +$467K |
|
38
CALL
SPDR Gold Trust
GLD
$131B
| $288K | 0.17% |
1,500
+500
| +50% | +$87.3K |
|
|
TRLV
39
Trulieve Cannabis Corp
TRLV
$1.66B
| $86K | 0.05% |
7,500
-42,500
| -85% | -$487K |
|
|
SLGCW
40
DELISTED
SomaLogic, Inc. Warrant
SLGCW
| $15K | 0.01% |
+20,000
| New | +$22.7K |
|
41
AdaptHealth
AHCO
$1.47B
| – | – |
-20,000
| Closed | -$321K |
|
42
PUT
Baxter International
BAX
$13.5B
| – | – |
-1,000
| Closed | -$78K |
|
43
BioCryst Pharmaceuticals
BCRX
$2.28B
| – | – |
-125,000
| Closed | -$2.03M |
|
|
44
CVS Health
CVS
$133B
| – | – |
-50,000
| Closed | -$5.06M |
|
|
45
PUT
CVS Health
CVS
$133B
| – | – |
-1,000
| Closed | -$101K |
|
|
46
Exelixis
EXEL
$13.3B
| – | – |
-200,000
| Closed | -$4.53M |
|
|
47
Gilead Sciences
GILD
$162B
| – | – |
-75,000
| Closed | -$4.46M |
|
|
HOLX
48
DELISTED
Hologic
HOLX
| – | – |
-15,000
| Closed | -$1.15M |
|
49
Henry Schein
HSIC
$9.77B
| – | – |
-50,000
| Closed | -$4.36M |
|
|
50
Medtronic
MDT
$109B
| – | – |
-75,000
| Closed | -$8.32M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Tamarack Advisers held 58 positions worth $173M, down 18% from $211M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Tamarack Advisers withdrew a net $5.29M in Q2 2022, closing 17 positions and reducing 11 holdings. Its most notable exit was Medtronic, an estimated $8.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Technology.
Against the trend, Tamarack Advisers opened a new position in Perrigo worth $8.11M.
- Tamarack Advisers's largest Q2 2022 buy was Perrigo: 200,000 shares worth $8.11M.
- Tamarack Advisers added most to Veradigm Inc. Common Stock in Q2 2022, an estimated $6.54M increase.
- Tamarack Advisers's biggest Q2 2022 reduction was Merck, cutting an estimated $7.09M.
- Tamarack Advisers fully exited Medtronic in Q2 2022, selling an estimated $8.32M.
- Tamarack Advisers's ten largest holdings make up 58% of its $173M portfolio in Q2 2022.
- Tamarack Advisers opened 12 new positions and closed 17 in Q2 2022.
- Tamarack Advisers's portfolio value fell 18% quarter-over-quarter to $173M.
Based on Tamarack Advisers's 13F filing for Q2 2022, filed 16 Aug 2022.